Skip to main content

Table 1 Patient characteristics by antipsychotic category

From: Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study

 

Clozapine

Risperidone

Olanzapine

Quetiapine

Ziprasidone

Haloperidol

Perphenazine

Other typicals

Number of treatment episodes

2,039

63,878

56,138

36,857

7,183

10,743

2,956

18,132

Duration of treatment, mean (SD), mo

16.0 (13.8)

10.5 (9.9)

9.9 (9.8)

9.7 (8.9)

7.1 (5.5)

9.8 (9.9)

10.2 (9.7)

9.5 (9.4)

Age, mean (SD), years

45 (16)

44 (25)

46 (21)

41 (20)

36 (16)

53 (21)

52 (19)

50 (18)

Males, %

54.4

46.3

45.3

39.4

41.8

46.5

36.7

40.2

With diagnosis of hyperprolactinemia during treatment, %

0.25

0.44

0.09

0.17

0.25

0.18

0.27

0.25

With prolactin test during treatment, %

1.52

2.06

1.15

1.41

1.84

0.94

1.05

1.08

With potentially prolactin-related symptoms during treatment, %*

9.1

7.1

6.5

7.9

7.9

6.0

7.1

7.0

With head/brain MRI or CT scan during treatment, %

16.8

12.1

11.4

11.9

8.5

13.8

11.6

13.7

With skull/brain injury or neoplasm 6 months prior to or during treatment, %†

4.17

3.94

4.11

3.87

2.28

8.02

2.64

6.48

With diagnosis of non-malignant pituitary tumor during treatment, %

        

Benign

0.15

0.13

0.05

0.06

0.11

0.08

0.03

0.07

Uncertain behavior

0.00

0.04

0.01

0.00

0.06

0.00

0.00

0.04

Unspecified

0.05

0.07

0.06

0.05

0.01

0.05

0.00

0.10

Malignant

0.05

0.03

0.01

0.01

0.00

0.02

0.00

0.03

Used another antipsychotic within 6 months prior to treatment, %

71.8

30.2

37.0

50.7

74.7

54.0

46.9

71.8

Concurrent use of other atypical antipsychotic, ratio of days supply to index antipsychotic days supply, mean (SD)

0.32 (0.41)

0.09 (0.25)

0.10 (0.25)

0.16 (0.32)

0.27 (0.39)

0.43 (0.45)

0.30 (0.42)

0.27 (0.40)

Concurrent use of other typical antipsychotic, ratio of days supply to index antipsychotic days supply, mean (SD)

0.16 (0.32)

0.05 (0.18)

0.07 (0.22)

0.07 (0.23)

0.08 (0.23)

0.04 (0.17)

0.05 (0.19)

0.07 (0.22)

Diagnoses, %:

        

Schizophrenia

84.4

24.9

30.3

27.5

42.5

52.2

38.3

38.4

Affective psychoses

46.2

50.7

57.1

63.4

64.1

39.0

52.4

40.2

Other psychoses

43.3

37.2

34.2

30.1

26.7

49.8

38.5

28.9

Other non-psychotic mental disorders

66.8

69.3

69.1

74.2

70.1

61.2

61.5

62.4

Health coverage:

        

Medicaid

75.6

64.0

62.4

62.5

55.4

75.0

71.9

73.6

HMO

12.5

20.9

19.8

18.0

20.5

15.4

14.7

14.3

Other health coverage

11.9

15.1

17.8

19.5

24.1

9.6

13.4

12.1

  1. *Gynecomastia, galactorrhea, oligomenorrhea, amenorrhea, dysmenorrhea, hypogonadism, hypothyroidism, infertility-male-hypospermatogenesis, infertility-female-pituitary/hypothalamic, impotence-organic, psychosexual dysfunction, genitourinary malfunctions arising from mental factors, and alopecia.
  2. † Based on following International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes: 851.xx to 854.xx, 900.82, 900.89 and 900.9 for brain or intracranial injury; 801.xx to 804.xx for skull injury; 191.xx, 198.3, 225.0 to 225.2, 237.5, and 239.6 for brain neoplasm and 170.9, 198.5, 213.9, 238.0 and 239.2 for skull neoplasm.
  3. CT, computed tomography, HMO, health maintenance organization; MRI, magnetic resonance imaging; SD, standard deviation.
Back to article page

Annals of General Psychiatry

ISSN: 1744-859X